广州市陌希生物技术

Moxi Biotech is a specialized biotechnology service provider based in Guangzhou, China, focusing on genome editing and cell engineering. The company offers a robust platform for CRISPR/Cas9-mediated gene modification, including the development of knockout, knockdown, and knock-in cell lines. Additionally, Moxi Biotech provides comprehensive viral vector services, encompassing the design and production of lentiviral, adenoviral, and adeno-associated virus (AAV) systems. Their services are widely utilized by academic institutions and biopharmaceutical companies for target validation, disease modeling, and drug screening. By integrating molecular biology expertise with high-throughput capabilities, Moxi Biotech accelerates the transition from basic research to clinical development.